Sanofi

sanofi.com

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

Related News

SANOFI, EXSCIENTIA LINK TO DEVELOP BISPECIFIC SMALL MOLECULE DRUGS

Sanofi | May 09, 2017

Under the alliance, Exscientia will use its platform to seek out and validate combinations of drug targets that could work synergistically and be amenable to its bispecific-small-molecule design strategy....

FDA APPROVES SANOFI AND REGENERON’S KEVZARA FOR ADULT RHEUMATOID ARTHRITIS

FDA | May 23, 2017

Sanofi and Regeneron Pharmaceuticals’ drug Kevzara (sarilumab) has received the US Food and Drug Administration (FDA) approval to treat adult patients affected with moderately to severely active rheumatoid arthritis (RA)....

SANOFI, PRINCIPIA AGREE TO DEVELOP MULTIPLE SCLEROSIS DRUG CANDIDATE

Sanofi | November 09, 2017

Sanofi will develop Principia Biopharma Inc.'s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, another central nervous system (CNS) diseases. Under the license agreement signed this week....

SANOFI EXPLORES COMBINATION TREATMENTS FOR MULTIPLE MYELOMA IN NEW LATE-STAGE TRIALS

Sanofi | December 07, 2017

Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment option for certain people with multiple myeloma, a rare blood cancer related to lymphoma and leukemia. Isatuximab is an investigational anti-CD38 monoclonal antibody being studied for the treatment of patients with relapsed and previously untreated multiple myeloma....